Supercharged immune cells take on childhood cancers
NCT ID NCT02789228
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new type of cell therapy for children and young adults with solid tumors that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are trained in the lab to recognize and attack multiple cancer-related targets. The main goal is to see if this approach is safe, while also checking for any signs that the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tumor associated antigen lymphocytes (TAA-CTL), a type of immune cell therapy
- What this could lead to
- If this works, it could point toward a new treatment option for children and young adults with hard-to-treat solid tumors that have not responded to standard therapy.
- What could go wrong
- This is a very early (Phase 1) and small study (28 participants) focused mainly on safety. The therapy may not shrink tumors or improve survival, and there is a risk of serious side effects like infusion reactions or graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's National Medical Center
Washington D.C., District of Columbia, 20010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can engineered immune cells tackle childhood sarcoma?